Survival Outcomes Related to Treatment Modalities in Patients With Oropharyngeal Squamous Cell Carcinoma

• Published in: Ear, nose, & throat journal p. 1455613221115608
• Main Authors: Cheng, Danni, Rao, Yufang, Qiu, Jianqing, Song, Yao, Pang, Wendu, Qiu, Ke, Dong, Yijun, Liu, Qiurui, Zhao, Yu, Liu, Jun, Xu, Wei, Ren, Jianjun
• Format: Journal Article
• Language: English
• Published: United States 15.07.2022
• Subjects: patient outcomes; real-world data; oropharyngeal cancer; HPV; surgery
• ISSN: 0145-5613; 1942-7522
• DOI: 10.1177/01455613221115608

More patients with oropharyngeal squamous cell carcinoma (OPSCC) in Eastern countries receive surgically inclusive treatment (SIT), while most patients in Western countries receive nonsurgical treatment (NST). The optimal treatment modality for OPSCC patients remains controversial. A total of 153 consecutive OPSCC cases diagnosed between 2009 and 2019 in West China Hospital (WCH) and 15,400 OPSCC cases from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2017) were obtained. Clinical characteristics, treatments, and survival outcomes were retrospectively collected. We constructed Kaplan-Meier curves and performed univariate (UVA) and multivariate (MVA) analyses to compare the prognosis of OPSCC patients among the WCH, SEER Asian, and SEER all ethnic populations by different treatment modality, human papilloma virus (HPV) infection status, age, and tumor stage. Overall, the proportions of patients with younger age, advanced tumors and HPV-negative status, and receiving SIT in WCH population were higher than those in the SEER all ethnic population, while the proportions in the SEER Asian population were between those of the other two populations. We observed consistent beneficial effects of SIT on the overall survival (OS) in OPSCC patients in all three populations (SEER Asian: MVA, hazard ratio (HR): 0.2, < .001; SEER all ethnic: MVA, HR: 0.46, < .001; WCH: UVA, HR: 0.62, = .071), and HPV-negative Asian patients showed greater benefits from the SIT than HPV-positive Asian patients (HPV Negative: HR: 0.16, = .005; HPV positive: HR = 0.28, = .059). Male was a risk factor for reduced OS in OPSCC patients in the WCH population (HR: 3.17, p = .043), but was a protective factor in the SEER population (HR: 0.8, = .002), which might be related to the differences of HPV infection status. Even though differences in patient characteristics existed between the Chinese, American, and Asian American populations, our ten-year real-world data and SEER data suggested that patients with OPSCC who received SIT had a better prognosis than those who received NST.